CoreWeave Selloff Validates WAIT Thesis as Bookings Mask Execution Risk

What happened

CoreWeave reported record Q1 bookings, but soft guidance and rising costs drove shares down ~13%. The market focused on the widening net loss ($740M) and interest expense ($536M) against $2.1B revenue. The DeepValue report's WAIT rating anticipated this tension: backlog ($99.4B) only converts when capacity is delivered and made available. The selloff does not yet trigger the bear case ($90) but reinforces the need for proof of on-time commissioning and stable financing. Until two quarters of delivery evidence emerge, buying the dip is premature.

Implication

The selloff brings the stock closer to the attractive entry ($95) but does not confirm it. Monitor 90-day checkpoints: facility availability and delivery timelines. If the company demonstrates on-time commissioning in Q2-Q3 without tightening financing, the base case ($125) becomes more likely. For now, patience is warranted given the downside asymmetry.

Thesis delta

No change to the WAIT rating. The market's reaction is consistent with the report's assessment that execution risk is underpriced. The stock's decline from $128 to $112 aligns with the bear scenario driver (delivery slippage concerns, though no formal delay yet). The thesis remains unchanged: wait for proof of backlog conversion before committing capital.